Iron versus cholesterol - Perspectives on the iron and heart: Disease debate

Journal of Clinical Epidemiology

Volumn 49, Issue 12, 1996, Pages 1345-1352

  Sullivan, Jerome L ^a  

^a RALPH H JOHNSON VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HEMOGLOBIN; IRON;

ARTICLE; CHOLESTEROL BLOOD LEVEL; DIETARY INTAKE; HEART INFARCTION; HEMOGLOBIN DETERMINATION; HUMAN; IRON STORAGE; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE;

EID: 0030464097     PISSN: 08954356     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-4356(96)00269-7     Document Type: Note

References (51)

1. 1. Kuhn TS. The Structure of Scientific Revolutions. Chicago: The University of Chicago Press; 1970.
2. 2. Sullivan JL. Conflicts of interest. Science 1992; 258: 1717.
3. 3. Sullivan JL. Iron and the sex difference in heart disease risk. Lancet 1981; 1: 1293-1294.
4. 4. Sullivan JL. The iron paradigm of ischemic heart disease. Am Heart J 1989; 117: 1177-1188.
5. 5. Sullivan JL. Stored iron as a risk factor for ischemic heart disease. In: Lauffer RB, Ed. Iron and Human Disease. Boca Raton: CRC Press; 1992.
6. 6. Sullivan JL. Stored iron and ischemic heart disease. Empirical support for a new paradigm. Circulation 1992; 86: 1036-1037.
7. 7. Babbs CF. Role of iron ions in the genesis of reperfusion injury following successful cardiopulmonary resuscitation: Preliminary data and a biochemical hypothesis. Ann Emerg Med 1985; 14: 777-783.
8. 8. Bernier M, Hearse DJ, Manning AS. Reperfusion-induced arrhythmias and oxygen-derived free radicals. Studies with anti-free radical interventions and a free-radical generating system in the isolated perfused rat heart. Circ Res 1986; 58: 331-340.
9. 9. Reddy BR, Kloner RA, Przyklenk K. Early treatment with deferoxamine limits myocardial ischemic/reperfusion injury. Free Rad Biol Med 1989; 7: 45-52.
10. 10. Lesnefsky EJ, Repine JE, Horwitz LD. Deferoxamine pretreatment reduces canine infarct size and oxidative injury. J Pharmacol Exp Therapeut 1990; 253: 1103-1108.
11. 11. Menasche P, Pasquier C, Bellucci S, Lorente P, Jaillon P, Piwnica A. Deferoxamine reduces neutrophil-mediated free radical production during cardiopulmonary bypass in man. J Thorac Cardiovasc Surg 1988; 96: 582-589.
12. 12. McCormick J, Skrabanek P. Coronary heart disease is not preventable by population interventions. Lancet 1988; 2: 839-841.
13. 13. Muldoon MF, Manuck SB, Matthews KA. Lowering cholesterol concentrations and mortality: A quantitative review of primary prevention trials. Br Med J 1990; 301: 309-314.
14. 14. Davey Smith G, Pekkanen J. Should there be a moratorium on the use of cholesterol lowering drugs? Br Med J 1992; 304: 431-434.
15. 15. Ravnskov U. Cholesterol lowering trials in coronary heart disease: Frequency of citation and outcome. Br Med J 1992; 305: 15-19.
16. 16. Kita T, Nagano Y, Yokode M, Ishii K, Kume N, Ooshima A, Yoshida H, Kawai C. Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. Proc Nad Acad Sci USA 1987; 84: 5928-5931.
17. 17. Carew TE, Schwenke DC, Steinberg D. Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: Evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Proc Natl Acad Sci USA 1987; 84: 7725-7729.
18. 18. Bjorkhem I, Henriksson-Freyschuss A, Breuer O, Diczfalusy U, Berglund L, Henriksson P. The antioxidant butylated hydroxytoluene protects against atherosclerosis. Arterioscler Thromb 1991; 11: 15-22.
19. 19. Stone NJ, Levy RI, Fredrickson DS, Verter J. Coronary artery disease in 116 kindred with familial type II hyperlipoproteinemia. Circulation 1974; 49: 476-488.
20. 20. Hill JS, Hayden MR, Frohlich J, Pritchard PH. Genetic and environmental factors affecting the incidence of coronary artery disease in heterozygous familial hypercholesterolemia. Arterioscler Thromb 1991; 11: 290-297.
21. 21. Sullivan JL, Till GO, Ward PA. Iron depletion decreases lung injury after systemic complement activation. Fed Proc 1986; 45: 452.
22. 22. Sullivan JL, Till GO, Ward PA, Newton RB. Nutritional iron restriction diminishes acute complement-dependent lung injury. Nutr Res 1989; 9: 625-634.
23. 23. Andrews FJ, Morris CJ, Lewis EJ, Blake DR. Effect of nutritional iron deficiency on acute and chronic inflammation. Ann Rheum Dis 1987; 46: 859-865.
24. 24. Chandler DB, Barton JC, Briggs DD, Butler TW, Kennedy JI, Grizzle WE, Fulmer JD. Effect of iron deficiency on bleomycin-induced lung fibrosis in the hamster. Am Rev Respir Dis 1988; 137: 85-89.
25. 25. Patt A, Horesh IR, Berger EM, Harken AH, Repine JE. Iron depletion or chelation reduces ischemia/reperfuston-induced edema in gerbil brains. J Pediatr Surg 1990; 25: 224-228.
26. 26. Salonen JT, Korpela H, Nyssonen K, Porkkala E, Tuomainen T-P, Belcher JD, et al. Lowering of body iron stores by blood letting and oxidation resistance of serum lipoproteins: A randomized cross-over trial in male smokers. J Intern Med 1995; 237: 161-168.
27. 27. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
28. 28. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-1307.
29. 29. Pedersen TR. Lowering cholesterol with drugs and diet. N Engl J Med 1995; 333: 1350-1351.
30. 30. Stampfer MJ, Rimm EB, Willett WC. Vitamin E and the risk of coronary disease. N Engl J Med 1993; 329: 1425-1426.
31. 31. Stampfer MJ, Colditz GA, Willett WC, et al. Postmenopausal estrogen therapy and cardiovascular disease - Ten-year follow-up from the Nurses' Health Study. N Engl J Med 1991; 325: 756-762.
32. 32. Goldman L, Tosteson ANA. Uncertainty about postmenopausal estrogen. N Engl J Med 1991; 325: 800-802.
33. 33. Posthuma WFM, Westendorp RGJ, Vandenbroucke JP. Cardioprotective effect of hormone replacement therapy in postmenopausal women: Is the evidence biased? Br Med J 1994; 308: 1268-1269.
34. 34. Stevens RG, Graubard BJ, Micozzi MS, Neriishi K, Blumberg BS. Moderate elevation of body iron level and increased risk of cancer occurrence and death. Int J Cancer 1994; 56: 364-369.
35. 35. Weinberg ED. Iron and infection. Microbiol Rev 1978; 42: 45-66.
36. 36. Lauffer RB, Ed. Iron and Human Disease. Boca Raton: CRC Press; 1992.
37. 37. Sullivan JL. Iron, plasma antioxidants, and the "oxygen radical disease of prematurity." Am J Dis Child 1988; 142: 1341-1344.
38. 38. Evans PJ, Evans R, Kovar IZ, Holton AF, Halliwell B. Bleomycin-detectable iron in the plasma of premature and full-term neonates. FEBS Lett 1992; 303: 210-212.
39. 39. Graham DY, Smith JL. Aspirin and the stomach. Ann Intern Med 1986; 104: 390-398.
40. 40. Owings DV, Kruskall MS, Thurer RL, Donovan LM. Autologous blood donation prior to elective cardiac surgery. Safety and effect on subsequent blood use. JAMA 1989; 262: 1963-1968.
41. 41. Buchwald H, Varco RL, Matts JP, Long JM, Fitch LL, Campbell GS, et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the program on the surgical control of the hyperlipidiemias (POSCH). N Engl J Med 1990; 323: 946-955.
42. 42. Danchin N. Is myocardial revascularization for tight coronary stenoses always necessary? Lancet 1993; 342: 224-5.
43. 43. Salonen JT, Nyyssonen K, Korpela H, Tuomilehto J, Seppanen R, Salonen R. High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. Circulation 1992; 86: 803-811.
44. 44. Stampfer MJ, Grodstein F, Rosenberg I, Willett W, Hennekens C. A prospective study of plasma ferritin and risk of myocardial infarction in US physicians (Abstract). Circulation 1993; 87: 688.
45. 45. Sullivan JL. Blood donation may be good for the donor. Iron, heart disease, and donor recruitment. Vox Sanguinis 1991; 61: 161-164.
46. 46. Meyers DG, Strickland D, Maloley PA, Seeburg JK, Wilson JE, McManus BF. The beneficial effect of blood donation on risk of vascular events. [Manuscript in preparation.]
47. 47. Ascherio A, Willett WC, Rimm EB, Giovannucci EL, Stampfer MJ. Dietary iron intake and risk of coronary disease among men. Circulation 1994; 89: 969-974.
48. 48. Rimm EB, Ascherio A, Stampfer MJ, Colditz GA, Giovannucci E, Willett WC. Dietary iron intake and risk of coronary disease among men (Abstract). Circulation 1993; 87: 962.
49. 49. Sempos CT, Looker AC, Gillum RF, Makuc DM. Body iron stores and the risk of coronary heart disease. N Engl J Med 1994; 330: 1119-1124.
50. 50. Stamler J, Stamler R, Brown V, Gotto AM, Greenland P, Grundy S, et al. Serum cholesterol. Doing the right thing. Circulation 1993; 88: 1954-1960.
51. 51. Pickering G. Physician and scientist. Br Med J 1964; ii: 1615-1619.